HOME
ABOUT US
OUR COMPANY
OUR TEAM
BOARD OF DIRECTORS
INVESTORS
CAREERS
T-GUARD®
CHARACTERISTICS
DEVELOPMENT PLAN
GRAFT-VERSUS-HOST
ADDITIONAL INDICATIONS
EXPANDED ACCESS
A PATIENT’S STORY
NEWS & EVENTS
NEWS
EVENTS
IN THE MEDIA
PUBLICATIONS
PARTNERING
PARTNERING FOR PROGRESS
CONTACT
✕
NEWS
Filter by
Languages
Skill level
Authors
Show all
All
Press-releases
All
2021
2019
2018
2017
2016
2015
2014
2013
2012
All
MauriceHampsink
8 september 2021
8 september 2021
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor
19 juli 2021
19 juli 2021
Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives
18 december 2019
18 december 2019
Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial
Load more